For the first time, drug overdoses have become the greatest cause of mortality for people under 50 in the United States. The opioid addiction crisis is rising out of control and leading to an increase in political and market pressure on drug companies from regulators, legislators, insurers, physicians, and patient advocacy groups. New FDA final guidelines for branded opioids were released at the beginning of 2017, and the final guidelines for generics are expected by the end of the year. How you prepare for and respond to them will shape the future of your company’s regulatory compliance and market success.